The pace of progress in the tools & diagnostics sector continues to accelerate. New technologies are being rapidly embraced by researchers leading to expansion into clinical use. The sector continues to be marked by significant M&A activity, but successful transactions require skillful advice for both buyer and seller.
The Diagnostics sector has enjoyed a surge in the recognition of its importance in a post-ACA environment. However, investors and consolidators alike are sharply focused on Clinical Validity, Clinical Utility, Economic Benefit, and Barriers to Competition.
We take pride in our ability to prepare and position our clients for capital markets and strategic transactions. Through this commitment to excellence, we have become a leading bookrunning manager of IPOs and follow-on offerings and an impactful M&A advisor.
We partner with our clients and are focused on their success and building long term relationships.